Immunotherapy reaches Breakthrough in eliminating HIV

13/06/2016 - 3 minutes

Immunocore has published key results for its new preclinical candidate for HIV, ImmTAV. This TCR-based immunotherapy has succeeded in targeting T-cells where HIV infection often ‘hides’ from drugs. 

immunocore_hiv_t-cell_tcr_immtavJust after presenting promising results from its leading candidate at ASCO 2016 (read our coverage here), Immunocore is making headlines in another area – infectious disease.

The UK-based Biotech has published key results of its HIV research in Nature‘s publication Molecular Therapy. Carried out in collaboration with the University of Oxford, the work outlines the application of TCR (a sort of sibling of CAR-T) to try to cure HIV.

While antiretrovirals have much improved the management of HIV, total cure is still currently out of reach for the 37 million people infected worldwide.

A major obstacle in finding a cure is to clear all the copies of HIV in the body (virus reservoirs). These copies persist in long-lived CD4+ T-cells,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member